89Zr-girentuximab
89Zr-TLX250-004
Phase 1 other completed
Quick answer
89Zr-girentuximab for Carcinoma, Renal Cell is a Phase 1 program (other) at Telix Pharmaceuticals Ltd with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Telix Pharmaceuticals Ltd
- Indication
- Carcinoma, Renal Cell
- Phase
- Phase 1
- Modality
- other
- Status
- completed